Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy

Puntiwa Oonsiri¹, Chonnipa Nantavinithya¹², Chawalit Lerbuttsayanukul², Thanaporn Sarsitthithum², Mananchaya Vimolnoch¹, Tanawat Tawonwong¹ and Kitwadee Saksornchai²*

Abstract

Background: Ultrahypofractionation can shorten the irradiation period. This study is the first dosimetric investigation comparing ultrahypofractionation using volumetric arc radiation therapy (VMAT) and intensity-modulated proton radiation therapy (IMPT) techniques in postmastectomy treatment planning.

Materials and methods: Twenty postmastectomy patients (10-left and 10-right sided) were replanned with both VMAT and IMPT techniques. There were four scenarios: left chest wall, left chest wall including regional nodes, right chest wall, and right chest wall including regional nodes. The prescribed dose was 26 Gy(RBE) in 5 fractions. For VMAT, a 1-cm bolus was added for 2 in 5 fractions. For IMPT, robust optimization was performed on the CTV structure with a 3-mm setup uncertainty and a 3.5% range uncertainty. This study aimed to compare the dosimetric parameters of the PTV, ipsilateral lung, contralateral lung, heart, skin, esophageal, and thyroid doses.

Results: The PTV-D95 was kept above 24.7 Gy(RBE) in both VMAT and IMPT plans. The ipsilateral lung mean dose of the IMPT plans was comparable to that of the VMAT plans. In three of four scenarios, the V5 of the ipsilateral lung in IMPT plans was lower than in VMAT plans. The Dmean and V5 of heart dose were reduced by a factor of 4 in the IMPT plans of the left side. For the right side, the Dmean of the heart was less than 1 Gy(RBE) for IMPT, while the VMAT delivered approximately 3 Gy(RBE). The IMPT plans showed a significantly higher skin dose owing to the lack of a skin-sparing effect in the proton beam. The IMPT plans provided lower esophageal and thyroid mean dose.

Conclusion: Despite the higher skin dose with the proton plan, IMPT significantly reduced the dose to adjacent organs at risk, which might translate into the reduction of late toxicities when compared with the photon plan.

Keywords: Proton therapy, Ultrahypofractionation, Postmastectomy, Breast irradiation

Introduction

There are many techniques and schedule schemes of treatment for breast irradiation [1]. The ultrahypofractionation is the recent new schedule that can shorten the irradiation period. This study is the first dosimetric investigation comparing ultrahypofractionation using volumetric arc radiation therapy (VMAT) and intensity-modulated proton radiation therapy (IMPT) techniques in postmastectomy treatment planning.

Adjuvant radiotherapy plays a significant role in local or locoregional breast cancer treatment. The omission of breast irradiation significantly increases the recurrence risk [2–5]. Routine breast irradiation using three-dimensional conformal radiotherapy (3D-CRT) is associated with long-term toxicity in organs at risk (OARs), such as the heart, the lungs, and the contralateral breast,
especially when regional node irradiation is required [6]. By using advanced techniques, such as intensity modulation radiotherapy (IMRT) or volumetric arc radiation therapy (VMAT), a high radiation dose could be delivered to the planning target volume (PTV) with high conformity. Although the high-dose regions of the lungs and heart are spared using these methods [7], but a higher volume of the adjacent OARs receives a low dose radiation, which can cause long term toxicities and secondary cancer [8]. A previous study used deep inspiration breath hold to reduce the radiation dose to the heart for left-side breast irradiation; however, a low dose to the remaining organs could not be eliminated [9].

With proton beam therapy (PBT), a well-known Bragg peak characteristic could potentially reduce the dose to OARs beyond the target almost completely. It is challenging to evaluate potential benefits for breast cancer, especially in chest wall treatment, which has a shallow depth. However, theoretically, proton therapy could reduce radiation doses to the lungs and heart by taking advantage of the rapid dose fall-off of the proton energy after the Bragg peak.

The conventional schedule for chest wall irradiation is 45–50 Gy in 25 fractions over 5 weeks. In the past decade, several trials investigated hypofractionation chest wall irradiation, defined as 43.5 Gy in 15 fractions for 3 weeks. Hypofractionation was noninferior to the standard scheme and with comparable toxicities to conventional fractionation among postmastectomy patients [10, 11]. A new study regimen of 26–27 Gy in 5 fractions for 1 week has been introduced in breast irradiation in the name of FAST-Forward [12]. Since the COVID-19 pandemic, ultrahypofractionated treatment has emerged as an option to reduce radiotherapy courses in the United Kingdom [13]. After the publication of the FAST-Forward study, the results showed that the acute skin reactions observed in FAST-Forward were mild and that the late normal tissue was noninferior to the results achieved using 43.5 Gy in 15 fractions [12, 14]. Breast irradiation with ultrahypofractionation has been applied in our department to reduce costs, and it may provide psychosocial benefits for patients [15, 16]. To our knowledge, there is no consensus on dose-volume constraints for PBT in ultrahypofractionation schemes. This is the dosimetric study to compare VMAT and intensity modulated proton radiation therapy (IMPT) in postmastectomy cancer patients.

Materials and methods

This study was approved by the Institutional Review Board (IRB: 017/64). Twenty postmastectomy patients (10-left and 10-right sided) who received breast irradiation at King Chulalongkorn Memorial Hospital were included in this study. The computed tomography (CT) datasets from their treatment were replanned using ultrahypofractionation with both VMAT and IMPT techniques. All patients were in the supine position and had a straight face with both arms over the head. The patient was immobilized using Vac-Lok (CIVCO Medical Solution, Iowa, USA) and knee support (CIVCO Radiotherapy, Iowa, USA). The image dataset was acquired by Siemens SOMATOM Definition AS 64-slice (Siemens, Erlangen, Germany) CT simulation with a 3-mm slice thickness. The scan range, from C2 to L2, included all breast tissue [17], while wires marked the area of the chest wall during simulation.

The clinical target volume (CTV) included the chest wall and regional nodes (i.e., supraclavicular, axillary (level I–III) and internal mammary nodes), and organs at risk were contoured and reviewed by at least 3 radiation oncologists who specialized in breast irradiation. The CTVs of the breast and regional lymph nodes were contoured based on the Radiotherapy Comparative Effectiveness atlas (RADCOMP) [18].

The PTV was a 5-mm expansion from the CTV but extracted from the skin surface for 5 mm and from the lung/chest wall interface for 3 mm. All organs at risk, including the ipsilateral and contralateral lungs and the heart, thyroid, and esophagus, were contoured. The skin, which was a layer of 5 mm inward from the body, was also created.

The wires placed during the simulation were overridden by a CT number of HU = −1000 to approximate the air density. The VMAT and IMPT plans were generated by the Eclipse treatment planning system version 15.6 (Varian Medical System. Inc., Palo Alto, CA). Each patient had 2 PTVs: the PTV chest wall and the PTV chest wall including regional nodes. Therefore, four scenarios were created: left chest wall, left chest wall including regional nodes, right chest wall, and right chest wall including regional nodes. The prescribed dose was an ultrahypofractionated dose of 26 Gy (RBE) in 5 fractions, employing a generic relative biological effectiveness (RBE) value of 1.1 for proton plans [19]. The VMAT optimization was planned with 6 MV photon beams. A 1-cm bolus was added for 2 in 5 fractions. The VMAT plans consisted of 4 arcs at gantry angles 240°–50° and 135°–310° for the right and left breasts, respectively. The collimator was rotated 90° for 2 arcs, splitting the jaw to cover the upper part and lower part of the PTV. This was done to increase the dose coverage in the PTV due to the limitation of the maximum leaf span of the MLCs in Varian linear accelerators of the X-direction jaw of only 16 cm [17]. The IMPT plans were created with two fields: an anteroposterior (AP) field (0°) and an anterior oblique field with a gantry angle ranging from ±30° to 45°.
depending on the beam direction to be as enface as possible to the chest wall. An example of a field arrangement is demonstrated in Fig. 1. A 5-cm range shifter was used to modify the beam dosimetric cover at all depths. This is the typical way to treat target at shallower depth than the minimum range of proton energy in proton treatment [20]. No bolus was applied to IMPT plans due to the reproducibility on bolus placement are seriously concern in proton treatment [20]. Additional targets were 0.5 cm for the proximal and distal margins and 1 cm for the lateral margin. Robust optimization was performed on the CTV structure with a 3-mm setup uncertainty and a 3.5% range uncertainty. The plans were normalized so that PTV received ≥ 95% of the prescription dose (95% of the prescribed dose was 24.7 Gy(RBE)) [6]. 

![Fig. 1](image)

**Fig. 1** Comparison of color wash isodose distribution for the left chest wall with and without regional lymph nodes for VMAT versus IMPT planning: **a** VMAT chest wall + regional nodes; **b** IMPT chest wall + regional nodes; **c** VMAT chest wall; **d** IMPT chest wall.
1% of the evaluation volume due to greater robustness than single point consideration [6]. STATA version 1.5.1 (Stata Corp LLL, Texas, USA) was used to perform statistical analysis. The paired t-test was used when data were normally distributed. The Wilcoxon signed-rank test was also used to analyze the difference in dose volume histogram between the VMAT and IMPT techniques in each scenario when the data did not follow a normal distribution. A $P$ value $<$ 0.05 was considered statistically significant.

**Discussion**

With low $\alpha/\beta$, breast cancer is one of few malignancies for which a high dose per fraction provides a benefit in killing cancer cells [21]. Hypofractionation is the current standard in adjuvant radiotherapy and has been increasingly used in many centers. A new ultrahypofractionation regimen has recently been introduced and has demonstrated noninferiority in terms of acute skin toxicity and oncological outcomes when compared to standard hypofractionation [14]. Brunt et al. [12] published results of the FAST-Forward trial and concluded that ultrahypofractionation, 26 Gy in 5 fractions for 1 week, did not show a significant difference in terms of patient-assessed normal tissue effects, clinician-assessed normal tissue effects, photographic changes in breast appearance, and oncological outcomes compared with 40 Gy in 15 fractions. With this short radiotherapy treatment course, this dose-fractionation regimen could be an option during the COVID-19 pandemic. Piras et al. [22] reported a dosimetric study of the FAST-Forward protocol of post-conservative surgery left breast cancer using the VMAT technique compared with the 3D-CRT technique, while our study compared VMAT with IMPT in postmastectomy plans. Piras’s results showed an ipsilateral lung V30 of 8.33 Gy, while our study revealed V20 approximately 6.4–7.6 Gy in VMAT plans. Our center aims to introduce ultrahypofractionation using proton beams; thus, dosimetric comparison of the target volume and OARs with VMAT is necessary. Although the DVH of most OARs except the ipsilateral lung in IMPT is clearly superior compared with those of VMAT in our study, we cannot assert that proton therapy will become the standard treatment in breast cancer in the near future. Further clinical studies are needed to assess whether the dosimetric advantage will translate into a clinical benefit. In addition, cost effectiveness should be considered. The cost of radiotherapy sessions and the cost of treatment for related toxicities must be weighed. However, we believe that in some special cases in which cardiac sparing is needed, proton therapy could be an appropriate alternative treatment [23].

Regarding toxicities, chest wall irradiation carries the risk of radiation pneumonitis, cardiac mortality, and secondary cancers [15, 24, 25]. Our study evaluated the dosimetric parameters of VMAT and IMPT for ultrahypofractionation postmastectomy in breast cancer. The PTV coverage was equivalent for IMPT versus VMAT plans. These results corresponded well with Ares’s study [6] which showed IMPT reduced the bath of low dose distribution for OARs. Our study demonstrated that the V5 and Dmean of the ipsilateral lung in IMPT were less than those in VMAT in 3 out of 4 scenarios. In lung cancer patients, the large volumes of lung that receive...
Table 1 The dosimetric comparison for the VMAT versus the IMPT plans

| Organs       | Dose levels | Lt. chest wall + regional nodes | Lt. chest wall | Rt. chest wall + regional nodes | Rt. chest wall |
|--------------|-------------|---------------------------------|----------------|----------------------------------|---------------|
|              |             | IMPT  | VMAT  | P value | IMPT  | VMAT  | P value | IMPT  | VMAT  | P value | IMPT  | VMAT  | P value |
| PTV          | Dmax (GyRBE) | 29.0±1.0 | 28.0±0.8 | <0.05 | 29.3±1.4 | 28.1±0.8 | <0.05 | 28.1±0.8 | 27.4±0.7 | 0.1 | 28.3±1.1 | 264±3.1 | 0.1 |
|              | D90 (GyRBE)  | 25.8±0.3 | 25.6±0.3 | 0.2 | 25.8±0.6 | 25.4±0.3 | <0.05 | 253±0.51 | 254±0.2 | 0.4 | 254±0.5 | 253±0.2 | 0.3 |
|              | D95 (GyRBE)  | 24.8±0.1 | 24.8±0.4 | 0.9 | 24.8±0.2 | 24.7±0.2 | 0.2 | 246±0.2 | 247±0.3 | 0.4 | 248±0.5 | 249±0.8 | 0.6 |
| Ipsilung     | Dmean (GyRBE) | 83±13 | 7.9±1.7 | 0.4 | 7.4±1.9 | 7.8±0.8 | 0.5 | 73±1.2 | 79±2.7 | 0.5 | 69±1.7 | 80±1.2 | 0.1 |
| V5 (%)       | 55.1±9.2 | 54.6±11.9 | 0.9 | 49.3±10.5 | 54.2±7.0 | <0.05 | 476±8.1 | 571±10.9 | <0.05 | 445±105 | 527±12.1 | 0.1 |
| V10 (%)      | 393±7.2 | 273±8.2 | <0.05 | 333±7.7 | 265±4.0 | <0.05 | 348±9.4 | 319±4.5 | 0.4 | 296±5.4 | 279±6.4 | 0.4 |
| V20 (%)      | 97±3.7 | 76±4.7 | <0.05 | 85±5.9 | 64±3.0 | 0.2 | 96±3.4 | 82±3.6 | 0.1 | 96±4.3 | 83±3.9 | 0.3 |
| Contra-lung  | Dmean (GyRBE) | 02±0.1–0.3 | 3.4±2.9–3.7 | <0.05 | 0.2 (0–0) | 3.1 (2.7–4.0) | <0.05 | 0.1 (0–0) | 3.1 (2.9–3.2) | <0.05 | 0 (0–0) | 2.6 (2.4–3.0) | <0.05 |
| V5 (%)       | 06±0.2–12 | 20.9±14.5–25 | <0.05 | 14.0 (11.1–26.8) | <0.05 | 15.8 (12.4–18.7) | <0.05 | 159 (94–15) | <0.05 | 109 (94–15) | <0.05 |
| V10 (%)      | 01±0–0.3 | 09.6±2.1 | <0.05 | 0 (0–0) | 0.8 (0.4–1.5) | <0.05 | 0 (0–0) | 0 (0–0) | <0.05 | 0 (0–0) | 0 (0–0) | <0.05 |
| Heart        | Dmax (GyRBE) | 169±7.0 | 19±4.2 | <0.05 | 169±10.4–25.5 | 186±18.3–22.0 | 0.3 | 106±4.8 | 101±4.8 | 0.7 | 84 (4.8–13.4) | 112 (8.4–14.5) | 0.4 |
|              | Dmean (GyRBE) | 11.0±6.2 | 4.6±4.4–4.7 | <0.05 | 1±0.7–1.5 | 5±4.6–5.6 | <0.05 | 0.4 (0–0.7) | 2.8 (2–3.4) | <0.05 | 0.5±0.2–0.8 | 3.3 (2.5–3.5) | <0.05 |
| V5 (%)       | 75±4.0 | 28.2±10.9 | <0.05 | 86 (4–6.102) | 33 (26.3–40.2) | <0.05 | 2.3 (1.6–4.7) | 106 (54.171) | <0.05 | 2.3 (0.5–5.6) | 16.3 (6–17.8) | <0.05 |
| V10 (%)      | 35±16.3 | 8.5±7.4–11.8 | <0.05 | 4 (1.1–5.2) | 12 (8.3–14.4) | <0.05 | 1.2 (0.2–2.2) | 1.7 (0–3) | 0.64 | 0.2 (0–1.2) | 1.1 (0–2.5) | 0.4 |
| V20 (%)      | 04±0.8 | 0.5±0.1–1.7 | 0.1 | 0 (0–0) | 0 (0–0) | 0 | 0 (0–0) | 0 (0–0) | 0 | 0 (0–0) | 0 (0–0) | 0.1 |
| Skin         | Dmax (GyRBE) | 284±12 | 27.3±0.9 | 0.1 | 284±19 | 27.3±0.8 | <0.05 | 282±1.1 | 268±0.6 | <0.05 | 282±1.4 | 268±0.6 | <0.05 |
|              | Dmean (GyRBE) | 245±11 | 234±10 | <0.05 | 247±17 | 23.2±0.9 | <0.05 | 252±1.7 | 233±0.7 | <0.05 | 249±0.8 | 233±0.6 | <0.05 |
| Esophagus    | Dmax (GyRBE) | 242±23 | 22.0±4.2 | <0.05 | 2.0 (0.6–3.8) | 8.783–96 | <0.05 | 198±4.3 | 194±4.3 | 0.7 | 0.2 (0.1–2.4) | 79 (56–98) | <0.05 |
|              | Dmean (GyRBE) | 45±17 | 7.0±1.7 | <0.05 | 0.2 (0–0.4) | 3.4 (2.8–3.5) | <0.05 | 29±1.2 | 5.7±0.9 | <0.05 | 0 (0–0.2) | 2.9 (2.5–3.0) | <0.05 |
| Thyroid      | Dmax (GyRBE) | 277±11 | 271±1.0 | 0.1 | 1.8 (1.2–2.8) | 0.8 (0.7–1) | 0.0 | 261±2.0 | 252±3.9 | 0.4 | 0.6 (0.0–1.6) | 0.8 (0.7–10) | 0.9 |
|              | Dmean (GyRBE) | 135±6.0 | 163±4.5 | 0.4 | 0.2 (0–0.3) | 0.5 (0–0.6) | <0.05 | 125±2.7 | 148±1.9 | <0.05 | 0.1 (0.0–0.3) | 0.5 (0–0.6) | <0.05 |

Mean ± SD for normally distributed data using a paired t-test; median (IQR) for nonnormally distributed data using the Wilcoxon signed-rank test
low-dose irradiation (5 Gy or 10 Gy) increase the rate of pneumonitis [26]. The volume of lung tissue receiving radiation could be associated with the risk of late toxicity, including second malignancy, particularly in young women. Our study confirmed that both high-dose and low-dose exposure to normal tissues were less common in the IMPT plan, which corresponded with MacDonald's report [24].

Heart dose is well known to be correlated with cardiac morbidity [27]. Our study supported that IMPT can reduce the potential risk to the cardiac structure. MacDonald's study [24] reported that proton therapy allows for the treatment of deep-seated lymph nodes, such as the internal mammary lymph node (IMN), with minimal cardiopulmonary doses. Our results also support that V5, V10 and the mean heart dose were much lower in IMPT than in VMAT. With this dosimetric advantage, lower long-term morbidity from heart disease could be expected from proton beam therapy.

One concern with IMPT to the chest wall from this study is the increased dose to the skin because of the lack of a skin-sparing effect with protons. However, the total dose of our regimen was only 26 Gy(RBE), and the actual differences in doses between IMPT and VMAT are
negligible. Therefore, acute skin toxicity, which typically relates to the total radiation dose, should not be greatly affected. We predict that this dose level is feasible and will be well-tolerated by patients. However, cosmesis is also an important outcome. Data collection in clinical studies is in progress and is reported in the near future.

Only 3 mm and 3.5% robust CTV optimization was sufficient and applied in this study because breathing motion management was concerned with access in clinical use. In addition, chest wall volumes are usually superficial in depth, ranging from 3 cm or less, and there was very little uncertainty about intrafraction motion for postmastectomy patients [23, 26]. Depauw et al. [28] reported that the patient’s chest wall movement along the AP/longitudinal direction was approximately 3 mm when motion management was performed during treatment. In addition, the beam path in proton plans is parallel to the target movement direction, which results in a minimal change in the position of the target; thus, the overall dosimetric impact is below 1% [6, 29].

Even though our study provided insights into proton and photon therapy in ultrahypofractionated postmastectomy irradiation, there are some limitations. First, only ten plans were evaluated for each scenario, and a large sample would provide more reliable data. Second, this is a dosimetric study, and the clinical outcomes of the proton interventions are needed. Nonetheless, the dose constraints to PTV and OARs of this study have been applied in our clinical practice, and we plan to report the clinical outcomes in the future. Additionally, this study does not compare the effectiveness of TCP and NTCP for both techniques. However, because this study’s dose comparison in OARs was based on an equivalent prescription dose, the physical dose comparison may be rational. Clinical outcomes pertinent to the TCP and NTCP will be reported in the future.

**Conclusion**

IMPT showed better normal tissue sparing while maintaining PTV coverage than VMAT in postmastectomy irradiation using ultrahypofractionation. Despite higher the dose to the skin in the IMPT group, the actual difference was negligible. IMPT could significantly reduce the dose to adjacent organs at risk, which could translate into reduced late toxicities compared with those of the photon plan. Further clinical studies are needed to prove the feasibility of this dose fractionation regimen using proton beam therapy. Our proposed dosing scheme would not strongly affect the acute toxicities and would be more convenient to use in COVID-19 pandemic situations.
Abbreviations
CT: Computed tomography; CTV: Clinical target volume; 3D-CRT: Three-dimensional conformal radiotherapy; DVHs: Dose volume histograms; IMPT: Intensity modulated proton radiation therapy; IMRT: Intensity modulation radiotherapy; PBT: Proton beam therapy; PTV: Planning target volume; VMAT: Volumetric arc radiation therapy; OARs: Organs at risk.

Acknowledgements
Not applicable.

Authors’ contributions
CL and TS participated in the study design. PO, KS, MW, and TT carried out the dose calculation and data collection. CN, KS, and PO drafted the manuscript. CL and KS helped to revise the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analyses during this work are included in this published article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Radiation Oncology, Department of Radiology, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
References

1. Yarnold J. Changes in radiotherapy fractionation-breast cancer. Br J Radiol. 2018;92(2017):8049. https://doi.org/10.1016/j.bjr.2017.08.049.

2. Veronesi U, Cazzanelli N, Marianni L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32. https://doi.org/10.1056/NEJMoa020989.

3. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96(2):115–21. https://doi.org/10.1093/jnci/djh013.

4. Group EBCTC. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Obstet Gynecol Surv. 2012;67(9):92–4. https://doi.org/10.1097/OGX.0b013e318247c712.

5. Wapnir II, Khan A. Current strategies for the management of locoregional breast cancer recurrence. Oncology. 2019;33(1):19–25.

6. Ares C, Khan S, MacArtain AM, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys. 2010;76(3):685–97. https://doi.org/10.1016/j.ijrobp.2009.02.062.

7. Liu H, Chen X, He Z, et al. Evaluation of 3D-CRT, IMRT and VMAT radiotherapy plans for left breast cancer based on clinical dosimetric study. Comput Med Imaging Graph. 2016;54:1–5. https://doi.org/10.1016/j.compmed.2016.10.001.

8. Karpf D, Sakka M, Metzger M, et al. Left breast irradiation with tangential intensity modulated radiotherapy (t-IMRT) versus tangential volumetric modulated arc therapy (t-VMAT): trade-offs between secondary cancer induction risk and optimal target coverage. Radiat Oncol. 2019;14(1):1–11. https://doi.org/10.1186/s13014-019-1363-4.

9. Oonsiri P, Wisetrinthong M, Chitnok M, et al. Radiation Oncology Department. Adv Radiat Oncol. 2021;6(6):100766. https://doi.org/10.1016/j.radonc.2021.100766.

10. Liu L, Yang Y, Guo Q, et al. Hypofractionation of conventional radiotherapy to improve local control in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020;15(1):1–15. https://doi.org/10.1186/s13014-020-1463-1.

11. Wang S, Fang H, Song YY, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352–60. https://doi.org/10.1016/S1470-2045(18)30813-1.

12. Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Foward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–20. https://doi.org/10.1016/S0140-6736(20)30926-2.

13. Spencer K, Jones CM, Girdler P, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021;22(3):309–20. https://doi.org/10.1016/S1470-2045(20)30743-9.

14. Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Foward trial. Radiother Oncol. 2016;120(1):114–8. https://doi.org/10.1016/j.radonc.2016.02.027.

15. MacDonald SM, Patel SA, Hickey S, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86(3):484–90. https://doi.org/10.1016/j.ijrobp.2013.01.038.

16. McClelland S, Achika FO, Bartlett GK, et al. Analysis of virtual versus in-person prospective peer review workflow in a multisite Academic Radiation Oncology Department. Adv Radiat Oncol. 2021;6(6):100766. https://doi.org/10.1016/j.adro.2021.100766.

17. Oonsiri P, Vannavijit C, Wimolnoch M, et al. Estimated radiation doses to ovarian and uterine organs in breast cancer irradiation using radio-photoluminescent glass dosimeters (RPLDs). J Med Radiat Sci. 2021;68(2):167–74. https://doi.org/10.1016/j.jmrds.2021.03.006.

18. MacDonald SA, C. Breast contouring radcomp consortium I; 2016. https://www.radcomp.org/LinkClick.aspx?fileticket=ZVeB451KQ3M%3d&tabid=Z429. Accessed 18 June 2021.

19. Paganietti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):407–21. https://doi.org/10.1016/S0360-3016(02)02754-2.

20. Lin H, Shi C, Huang S, et al. Applications of various range shifters for proton pencil beam scanning radiotherapy. Radiat Oncol. 2021;16:146. https://doi.org/10.1186/s13014-021-01873-8.

21. Ray KJ, Sibson NR, Kiftie AE. Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits. Clin Oncol. 2015;27(7):420–6. https://doi.org/10.1016/j.clon.2015.02.008.

22. Piras A, Memma S, DiAverio A, et al. New fractionations in breast cancer: a dosimetric study of 3D-CRT versus VMAT. J Med Radiat Sci. 2021. https://doi.org/10.1016/j.jrms.2021.

23. Lundkvist J, Ekman M, Ericsson S, et al. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75(2):179–85. https://doi.org/10.1016/j.radonc.2005.03.006.

24. MacDonald SM, Jimenez R, Paetzold P, et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. Radiat Oncol. 2013;8(1):1–7. https://doi.org/10.1186/1748-717X-8-71.

25. Hernandez M, Zhang R, Sanders M, et al. A treatment planning comparison of volumetric modulated arc therapy and proton therapy for a sample of breast cancer patients treated with post-mastectomy radiotherapy. J Proton Ther. 2015;11(1):119. https://doi.org/10.4319/jpt.2015.11.9.

26. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemother-apy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66(5):1399–407. https://doi.org/10.1016/j.ijrobp.2006.07.1337.

27. Højris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBGC 82b and 82c randomised trials. Lancet. 1999;354(9188):1425–30. https://doi.org/10.1016/S0140-6736(99)02245-x.

28. Depauw N, Batin E, Daartz J, et al. A novel approach to postmastectomy radiation therapy using scanned proton beams. Int J Radiat Oncol Biol Phys. 2015;91(2):427–34. https://doi.org/10.1016/j.ijrobp.2014.10.039.

29. Cuaron JJ, MacDonald SM, Cahlon O. Novel applications of proton therapy in breast carcinoma. Chin Clin Oncol. 2016;5(4):52. https://doi.org/10.21037/ccio.2016.06.04.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.